Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

16.98 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Greenwich LifeSciences, Inc. - Common stock

< Previous 1 2 3 4 Next >

3 Stocks Insiders Are Snapping Up. Do They Know Something We Don’t? ↗

October 05, 2021

Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits.

Via InvestorPlace

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

September 28, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference

September 27, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

September 23, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 13, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

September 09, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference

September 07, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Set to Join Russell 2000® Index

June 08, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021 ↗

September 01, 2021

Upgrades For Chatham Lodging Trust (NYSE:

Via Benzinga

Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence ↗

June 07, 2021

Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have...

Via Benzinga

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated

June 07, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 02, 2021

Gainers Tilray (NASDAQ:TLRY) shares incre...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 22, 2021

Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million...

Via Benzinga

Topics Artificial Intelligence

1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences? ↗

April 21, 2021

The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?

Via The Motley Fool

Topics Initial Public Offering

Insider Buys Greenwich LifeSciences Shares ↗

April 14, 2021

Greenwich LifeSciences Inc (NASDAQ:GLSI) was trading 4.4% higher from the previous closing price. CEO Patel Snehal filed a Form 4 with the SEC on Wednesday, April 14. The...

Via Benzinga

Topics Regulatory Compliance

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 14, 2021

Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0...

Via Benzinga

Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

April 14, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 12, 2021

Gainers Intec Pharma (NASDAQ:NTEC) shares increased by 7.67% to $4.35 during Monday's after-market session. Intec Pharma's trading volume hit 412 shares by close,...

Via Benzinga

55 Biggest Movers From Yesterday ↗

April 13, 2021

Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with...

Via Benzinga

Why Greenwich LifeSciences Stock Tanked Today ↗

April 12, 2021

The drop came despite the clinical-stage biotech announcing good news over the weekend.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 12, 2021

Gainers 180 Life Sciences (NASDAQ:ATNF) shares increased by 27.31% to $12.4 during Monday's regular session. Trading volume for 180 Life Sciences's stock is 29.3...

Via Benzinga

42 Stocks Moving In Monday's Mid-Day Session ↗

April 12, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake...

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; Microsoft To Acquire Nuance ↗

April 12, 2021

Following the market opening Monday, the Dow traded down 0.27% to 33,708.58 while the NASDAQ fell 0.54% to 13,825.03. The S&P also fell, dropping 0.20% to 4,120.48. The U.S....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 12, 2021

Gainers Auris Medical Holding (NASDAQ:EARS) stock increased by 21.8% to $5.25 during Monday's pre-market session. The company's market cap stands at $67.5 million...

Via Benzinga

28 Stocks Moving in Monday's Pre-Market Session ↗

April 12, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) rose 73.6% to $9.65 in pre-market trading. Modell's Sporting Goods reported a stake of 18.4% in a 13D filing on Friday....

Via Benzinga

REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

April 12, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

April 10, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

51 Biggest Movers From Friday ↗

April 12, 2021

Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and...

Via Benzinga

38 Stocks Moving In Friday's Mid-Day Session ↗

April 09, 2021

Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize...

Via Benzinga

Why Greenwich LifeSciences Stock Is Rising Today ↗

April 09, 2021

The company reported positive data for its cancer immunotherapy candidate GP2.

Via The Motley Fool

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.